

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Infectious disease</b>				
<i>Pseudomonas</i>	Toll-like receptor 5 (TLR5); IL-1 $\beta$	<p>Cell culture studies suggest agonizing TLR5 and IL-1<math>\beta</math> could be useful for treating pulmonary <i>Pseudomonas aeruginosa</i> infection. In cell culture, mouse alveolar macrophages lacking Tlr5 or Il-1<math>\beta</math> had lower activity against <i>P. aeruginosa</i> than wild-type macrophages. Next steps including testing whether TLR5 agonists could increase macrophage killing of <i>P. aeruginosa</i> <i>in vitro</i> and in animal models.</p> <p>Cleveland BioLabs Inc.'s CBLB502, a bacteria-derived TLR5 agonist, is in Phase II testing for acute radiation syndrome (ARS) and in preclinical development for colorectal cancer and renal damage.</p>	Work unpatented; licensing status not applicable	<p>Descamps, D. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Jan. 17, 2012; doi:10.1073/pnas.1108464109</p> <p><b>Contact:</b> Jean-Michel Sallenave, Pasteur Institute, Paris, France e-mail: <a href="mailto:jms@pasteur.fr">jms@pasteur.fr</a></p> <p><b>Contact:</b> Bénédicte Manoury, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France e-mail: <a href="mailto:benedicte.manoury@inserm.fr">benedicte.manoury@inserm.fr</a></p>
<p><b>SciBX 5(5); doi:10.1038/scibx.2012.128</b> Published online Feb. 2, 2012</p>				